Publications by authors named "Katelyn Rowland"

Claim this Profile
G
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.
Amy McMichael, Mona Shahriari, Linda Stein Gold, Theodore Alkousakis, Olivia Choi, Katelyn Rowland

JAMA Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.
Andrew Alexis, Amy McMichael, Jennifer Soung, Olivia Choi, Theodore Alkousakis, Katelyn Rowland

JAMA Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.
Bruce E Strober, Jud C Janak, Timothy Fitzgerald, Maya Marchese, Rachel E Teneralli, Katelyn Rowland

J Drugs Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement.
Linda Stein Gold, Alice B Gottlieb, April W Armstrong, Theodore Alkousakis, Robert Bissonnette, Katelyn Rowland

Br J Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Bruce Strober, Laura C Coates, Mark G Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland

Drug Saf· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Andrew Blauvelt, Mark Lebwohl, Richard G Langley, Katelyn Rowland, Ya-Wen Yang

J Am Acad Dermatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
Mark G Lebwohl, Joseph F Merola, Katelyn Rowland, Megan Miller, Ya-Wen Yang

Br J Dermatol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
April W Armstrong, Timothy Fitzgerald, Robert R McLean, Amanda Teeple, Jonathan P Uy, Katelyn Rowland

Adv Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
April W Armstrong, Timothy Fitzgerald, Robert R McLean, Amanda Teeple, Jonathan P Uy, Katelyn Rowland

Dermatol Ther (Heidelb)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
April W Armstrong, Timothy Fitzgerald, Robert R McLean, Amanda Teeple, Jonathan P Uy, Katelyn Rowland

Dermatol Ther (Heidelb)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database.
Timothy Fitzgerald, Aimee M Near, Hyunchung Kim, Amanda Teeple, Mobolaji Olurinde, Katelyn Rowland

Dermatol Ther (Heidelb)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
Jessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, Soumya D Chakravarty, Timothy Fitzgerald, Katelyn Rowland

Dermatol Ther (Heidelb)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and Application of a New Bacterial Biosensor for the Presumptive Detection of Gunshot Residue.
Amorette E Barber, Harley Hodges, Sarah E G Porter, Elle Richardson, Katelyn Rowland

J Vis Exp· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis